Atlas Trials

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Clinical trial NCT07262164 · RECRUITING

Trial details

NCT number
NCT07262164
Sponsor
Shanghai Virogin Biotech Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Malignant Solid Tumor
Start date
2026-03-18
Primary completion
2027-05-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.